First Time Loading...

Biogen Inc
NASDAQ:BIIB

Watchlist Manager
Biogen Inc Logo
Biogen Inc
NASDAQ:BIIB
Watchlist
Price: 202.46 USD 0.23% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. [ Read More ]

The intrinsic value of one BIIB stock under the Base Case scenario is 217.7 USD. Compared to the current market price of 202.46 USD, Biogen Inc is Undervalued by 7%.

Key Points:
BIIB Intrinsic Value
Base Case
217.7 USD
Undervaluation 7%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Biogen Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BIIB stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Biogen Inc

Provide an overview of the primary business activities
of Biogen Inc.

What unique competitive advantages
does Biogen Inc hold over its rivals?

What risks and challenges
does Biogen Inc face in the near future?

Has there been any significant insider trading activity
in Biogen Inc recently?

Summarize the latest earnings call
of Biogen Inc.

What significant events have occurred
in Biogen Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Biogen Inc.

Provide P/S
for Biogen Inc.

Provide P/E
for Biogen Inc.

Provide P/OCF
for Biogen Inc.

Provide P/FCFE
for Biogen Inc.

Provide P/B
for Biogen Inc.

Provide EV/S
for Biogen Inc.

Provide EV/GP
for Biogen Inc.

Provide EV/EBITDA
for Biogen Inc.

Provide EV/EBIT
for Biogen Inc.

Provide EV/OCF
for Biogen Inc.

Provide EV/FCFF
for Biogen Inc.

Provide EV/IC
for Biogen Inc.

Show me price targets
for Biogen Inc made by professional analysts.

What are the Revenue projections
for Biogen Inc?

How accurate were the past Revenue estimates
for Biogen Inc?

What are the Net Income projections
for Biogen Inc?

How accurate were the past Net Income estimates
for Biogen Inc?

What are the EPS projections
for Biogen Inc?

How accurate were the past EPS estimates
for Biogen Inc?

What are the EBIT projections
for Biogen Inc?

How accurate were the past EBIT estimates
for Biogen Inc?

Compare the revenue forecasts
for Biogen Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Biogen Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Biogen Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Biogen Inc compared to its peers.

Compare the P/E ratios
of Biogen Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Biogen Inc with its peers.

Analyze the financial leverage
of Biogen Inc compared to its main competitors.

Show all profitability ratios
for Biogen Inc.

Provide ROE
for Biogen Inc.

Provide ROA
for Biogen Inc.

Provide ROIC
for Biogen Inc.

Provide ROCE
for Biogen Inc.

Provide Gross Margin
for Biogen Inc.

Provide Operating Margin
for Biogen Inc.

Provide Net Margin
for Biogen Inc.

Provide FCF Margin
for Biogen Inc.

Show all solvency ratios
for Biogen Inc.

Provide D/E Ratio
for Biogen Inc.

Provide D/A Ratio
for Biogen Inc.

Provide Interest Coverage Ratio
for Biogen Inc.

Provide Altman Z-Score Ratio
for Biogen Inc.

Provide Quick Ratio
for Biogen Inc.

Provide Current Ratio
for Biogen Inc.

Provide Cash Ratio
for Biogen Inc.

What is the historical Revenue growth
over the last 5 years for Biogen Inc?

What is the historical Net Income growth
over the last 5 years for Biogen Inc?

What is the current Free Cash Flow
of Biogen Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Biogen Inc.

Financials

Balance Sheet Decomposition
Biogen Inc

Current Assets 6.9B
Cash & Short-Term Investments 1B
Receivables 2.1B
Other Current Assets 3.7B
Non-Current Assets 20B
Long-Term Investments 745m
PP&E 3.7B
Intangibles 14.6B
Other Non-Current Assets 928.6m
Current Liabilities 3.4B
Accounts Payable 403.3m
Accrued Liabilities 1.7B
Other Current Liabilities 1.4B
Non-Current Liabilities 8.6B
Long-Term Debt 6.8B
Other Non-Current Liabilities 1.8B
Efficiency

Earnings Waterfall
Biogen Inc

Revenue
9.8B USD
Cost of Revenue
-2.5B USD
Gross Profit
7.3B USD
Operating Expenses
-5.3B USD
Operating Income
2B USD
Other Expenses
-888.8m USD
Net Income
1.2B USD

Free Cash Flow Analysis
Biogen Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

BIIB Profitability Score
Profitability Due Diligence

Biogen Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive Operating Income
Positive 3-Year Average ROE
57/100
Profitability
Score

Biogen Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

BIIB Solvency Score
Solvency Due Diligence

Biogen Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
55/100
Solvency
Score

Biogen Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BIIB Price Targets Summary
Biogen Inc

Wall Street analysts forecast BIIB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BIIB is 306.71 USD with a low forecast of 217.15 USD and a high forecast of 525 USD.

Lowest
Price Target
217.15 USD
7% Upside
Average
Price Target
306.71 USD
51% Upside
Highest
Price Target
525 USD
159% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

BIIB Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

BIIB Price
Biogen Inc

1M 1M
-5%
6M 6M
-16%
1Y 1Y
-30%
3Y 3Y
-25%
5Y 5Y
-12%
10Y 10Y
-22%
Annual Price Range
202.46
52w Low
190.52
52w High
318.06
Price Metrics
Average Annual Return 5.59%
Standard Deviation of Annual Returns 18.97%
Max Drawdown -55%
Shares Statistics
Market Capitalization 29.3B USD
Shares Outstanding 145 700 000
Percentage of Shares Shorted 2.76%

BIIB Return Decomposition
Main factors of price return

What is price return decomposition?

BIIB News

Other Videos

Last Important Events
Biogen Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Biogen Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Biogen Inc Logo
Biogen Inc

Country

United States of America

Industry

Biotechnology

Market Cap

29.3B USD

Dividend Yield

0%

Description

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 9,610 full-time employees. The company is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. The company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.

Contact

MASSACHUSETTS
Cambridge
225 Binney St
+17814642000.0
https://www.biogen.com/

IPO

1991-09-17

Employees

9 610

Officers

President, CEO & Director
Mr. Christopher A. Viehbacher
Executive VP & CFO
Mr. Michael R. McDonnell CPA
Head of Pharmaceutical Operations & Technology
Ms. Nicole Murphy
Executive VP & Chief Legal Officer
Ms. Susan H. Alexander Esq.
Executive VP & Chief Human Resources Officer
Dr. Ginger Gregory
Senior VP & Chief Accounting Officer
Ms. Robin C. Kramer
Show More
Senior VP & Head of Investor Relations
Mr. Charles E. Triano
Chief Communication Officer & Head of Corporate Affairs
Ms. Natacha Gassenbach
Executive VP & Head of Corporate Development
Mr. Adam Keeney Ph.D.
President & Head of North America
Ms. Alisha A. Alaimo
Show Less

See Also

Discover More
What is the Intrinsic Value of one BIIB stock?

The intrinsic value of one BIIB stock under the Base Case scenario is 217.7 USD.

Is BIIB stock undervalued or overvalued?

Compared to the current market price of 202.46 USD, Biogen Inc is Undervalued by 7%.